Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Etonogestrel
Drug ID BADD_D00852
Description Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel.[A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.[L5692]
Indications and Usage Etonogestrel is administered in subdermal implants as long-acting reversible contraception. It is known to be effective in postpartum insertion including breastfeeding women.[A175990] Etonogestrel is part of the long-acting contraceptive implants that prevent pregnancy. The implant's effect can remain for 5 years.[L5698]
Marketing Status approved; investigational
ATC Code G03AC08
DrugBank ID DB00294
KEGG ID D04104
MeSH ID C044815
PubChem ID 6917715
TTD Drug ID D02KIU
NDC Product Code 64918-1500; 78206-145; 71161-147; 63190-0260; 45541-1192; 60870-0475; 63190-0480; 64918-1906; 65089-0053
UNII 304GTH6RNH
Synonyms etonogestrel | 13-ethyl-17-hydroxy-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one | 3-oxodesogestrel | 3-ketodesogestrel | 3-oxo desogestrel | 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17-alpha)- | 3-keto-desogestrel | ORG-3236 | Implanon | nexplanon
Chemical Information
Molecular Formula C22H28O2
CAS Registry Number 54048-10-1
SMILES CCC12CC(=C)C3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Implant site pruritus08.02.02.060; 12.07.02.060; 23.03.12.0130.093914%-
Implant site rash08.02.02.061; 12.07.02.061; 23.03.13.0260.027998%-
Implant site scar08.02.02.062; 12.07.02.062; 23.03.11.0330.053598%-
Implant site swelling08.02.02.063; 12.07.02.0630.071887%-
Implant site thrombosis08.02.02.064; 12.07.02.064; 24.01.01.0410.000235%-
Implant site urticaria08.02.02.066; 10.01.06.016; 12.07.02.066; 23.04.02.0160.011143%-
Implant site vesicles08.02.02.067; 12.07.02.067; 23.03.01.0350.012624%-
Implant site warmth08.02.02.068; 12.07.02.0680.010814%-
Injection site scab08.02.03.069; 12.07.03.069; 23.03.03.0880.000799%-
Intercostal neuralgia17.02.07.0250.000235%-
Intermenstrual bleeding21.01.01.0150.219751%-
Lactation insufficiency18.06.02.006; 21.05.02.0060.002821%-
Limb mass15.03.05.0190.001434%-
Lung opacity22.12.01.0060.000235%-
Medical device site bruise08.07.01.017; 12.02.21.001; 23.03.11.038; 24.07.06.0310.000517%-
Medical device site discomfort08.07.01.021; 12.02.21.0050.038788%-
Medical device site fibrosis08.07.01.026; 12.02.21.0100.000917%-
Medical device site granuloma08.07.01.027; 12.02.21.011; 23.03.15.0140.000353%-
Medical device site movement impairment08.07.01.036; 12.02.21.0200.001434%-
Medical device site reaction08.07.01.038; 12.02.21.0220.000517%-
Medical device site scab08.07.01.039; 12.02.21.023; 23.03.03.0920.001834%-
Morning sickness07.01.07.018; 18.02.02.0220.003432%-
Perinatal depression18.06.03.003; 19.15.01.0110.000752%-
Pregnancy on contraceptive18.08.01.0040.001998%-
Pregnancy with implant contraceptive08.07.04.003; 18.08.01.0060.122358%-
Procedural failure08.06.01.0440.000799%-
Reaction to excipient10.01.01.0420.000353%-
Superficial vein thrombosis24.01.02.0160.000917%-
Therapeutic product ineffective08.06.01.0570.000917%-
Unwanted pregnancy18.08.01.0080.000235%-
The 13th Page    First    Pre   13 14    Next   Last    Total 14 Pages